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Abstract
Background: Abuse of addictive substances is a serious problem that has a significant impact on areas such as health, 
the economy, and public safety. Heroin use among young women of reproductive age has drawn much attention 
around the world. However, there is a lack of information on effects of prenatal exposure to opioids on their offspring. 
In this study, an animal model was established to study effects of prenatal exposure to opioids on offspring.
Methods: Female pregnant Sprague-Dawley rats were sub-grouped to receive (1) vehicle, (2) 2-4 mg/kg morphine (1 
mg/kg increment per week), (3) 7 mg/kg methadone, and (4) 3 mg/kg buprenorphine, subcutaneously, once or twice 
a day from E3 to E20. The experiments were conducted on animals 8-12 weeks old and with body weight between 250 
and 350 g.
Results: Results showed that prenatal exposure to buprenorphine caused higher mortality than other tested 
substance groups. Although we observed a significantly lower increase in body weight in all of the opioid-
administered dams, the birth weight of the offspring was not altered in all treated groups. Moreover, no obvious 
behavioral abnormality or body-weight difference was noted during the growing period (8-12 weeks) in all offspring. 
When the male offspring received morphine injection twice a day for 4 days, the prenatally opioid-exposed rats more 
quickly developed a tolerance to morphine (as shown by the tail-flick tests), most notably the prenatally 
buprenorphine-exposed offspring. However, the tolerance development to methadone or buprenorphine was not 
different in offspring exposed prenatally to methadone or buprenorphine, respectively, when compared with that of 
the vehicle controlled group. Similar results were also obtained in the female animals.
Conclusions: Animals prenatally exposed to morphine, methadone, or buprenorphine developed tolerance to 
morphine faster than their controlled mates. In our animal model, prenatal exposure to buprenorphine also resulted in 
higher mortality and much less sensitivity to morphine-induced antinociception than prenatal exposure to morphine 
or methadone. This indicates that buprenorphine in higher doses may not be an ideal maintenance drug for treating 
pregnant women. This study provides a reference in selecting doses for clinical usage in treating pregnant heroin 
addicts.
Background
Opioid drugs are the most effective therapeutic analgesic
for chronic pain and cancer pain. Continual use of opi-
oids, however, results in the development of tolerance
and dependence. Moreover, widespread abuse of opioids
(heroin and/or morphine) causes serious social and eco-
nomic problems around the world. According to the U.S.
National Survey on Drug Use and Health, 5.2% of preg-
nant women ages 15 to 44 used illicit drugs in 2006-2007
[1]. In the United States, the average rate of illicit drug
use increased slightly from 3.9% in 2004-2005 to 5.2% in
2006-2007. The U.S. study indicates that illicit drug use
during pregnancy is a growing problem. In opioid addic-
tion, children born to heroin- or morphine-addicted
mothers have been known to suffer from higher mortality
and deficiency in the central nerve system [2,3]. Those
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sequel caused by dysfunction in intellectual ability and in
emotional control during their school years [4-6]. These
findings underscore the importance of investigating the
effects of prenatal opioid exposure in offspring.
Methadone is a synthetic μ-opioid receptor agonist; it is
also an antagonist for N-methyl-D-aspartate (NMDA)
receptor, which is based on its racemic structure [7].
Methadone is commonly utilized in detoxification and
maintenance programs for heroin-addicted patients,
including pregnant women [8-10]. Methadone mainte-
nance treatment for heroin addicted mothers had been
reported to result in lower maternal morbidity/mortality
rates and to promote fetal stability and growth, as com-
pared with pregnant women not under methadone main-
tenance treatment [8,10]. However, high doses of
methadone have been found to cause higher neonatal
abstinence syndrome (NAS) in offspring [11], suggesting
that methadone is not ideal to treat pregnant opioid
addicts.
Buprenorphine is a well-established opioid analgesic
that recently has been used to treat heroin addiction.
Buprenorphine shows complex interactions with various
opioid receptor subtypes. It has high affinity to μ- and κ-
opioid receptors and also binds to ORL-1 (opioid recep-
tor-like 1) receptor [12,13]. Mu- and κ-opioid and ORL-1
receptor are all expressed in the central nerve system dur-
ing early prenatal development, hence the use of opioids
may affect these receptors during the prenatal period.
Recent studies show that buprenorphine maintenance, a
new approach to treat heroin dependence, has a lower
risk of neonatal abstinence syndrome than methadone
[14,15], suggesting that buprenorphine is safer than
methadone to treat opioid-addicted women during preg-
nancy. However, animal studies showed that prenatal
exposure to higher dose (1 mg/kg) of buprenorphine
affected the myelination in the developing brain [16],
indicating that opioid signals played an important role in
regulating the brain development of innervations, espe-
cially in neuronal axons. The long-term effects of
buprenorphine treatment during pregnancy in offspring
await further investigation.
Tolerance, the progressive diminution of the suscepti-
bility to the effects of a drug, is an important phenome-
non that occurs after chronic opioid administration.
Tolerance to morphine-induced analgesia has been found
in prenatally morphine-exposed offspring [17-19]. Yet,
more studies are needed to investigate tolerance or cross-
tolerance development after prenatal exposure to mainte-
nance drugs such as methadone and buprenorphine.
Therefore, we aimed to investigate if the prenatal
administration of opioids altered antinociceptive effects
of supraspinal analgesia induced by postnatal systemic
morphine, methadone, or buprenorphine. The results
demonstrate that prenatal administration of morphine,
methadone, and buprenorphine brought about the devel-




Pregnant Sprague-Dawley rats (BioLASCO Taiwan Co.,
Ltd) and their offspring were used in the experiments.
After arrival, the dams were acclimatized to a room with
controlled temperature (25°C), humidity (50 ± 10%) and a
12-h day-night cycle (light on 07:00-19:00 h) for 24 hours
before experimentation. Pregnant rats were kept individ-
ually in separate cages, and their offspring were housed 2-
3 per cage after weaning. All animals were provided with
food (Western Lab 7001, Orange, CA, USA) and water ad
libitum. The ethical guidelines provided by Laboratory
Animal Center of the National Health Research Institutes
were followed throughout the study.
Drugs
Morphine (NBCD, Taiwan), methadone (USP, USA), and
buprenorphine (Sigma Aldrich, USA) were dissolved in
distilled water and were administrated subcutaneously
(s.c.) in a volume of 1.0 ml/kg of body weight.
Heroin is a major drug of abuse by addicts, however, it
is rapidly converted to morphine after crossing the blood
brain barrier into the central nervous system. Accord-
ingly, we used morphine directly as a test agent in this
study.
Prenatal treatments
Pregnant Sprague-Dawley female rats, 10-12 weeks old
and weighing 200-250 g, were randomly assigned to dif-
ferent groups and were s.c. injected with opioids or vehi-
cle during the gestational period (E3 to E20). The dose of
opioids used in pregnant rats was selected based on the
studies reported previously [17,20]. The treatment proto-
cols for these groups are as follows. Group 1 (vehicle con-
trol) rats received 1X phosphate buffer saline 1 ml/kg, s.c.,
twice a day from E3 to E20. Group 2 (morphine) rats
received morphine, 2 mg/kg (initial dose), s.c., twice a day
in the first week; the dose was increased by 1 mg/kg every
week until the final dose reached 4 mg/kg. Group 3
(methadone) rats received methadone, 7 mg/kg, s.c.,
twice a day from E3 to E20. Group 4 (buprenorphine) rats
received buprenorphine, 3 mg/kg, s.c., once a day from E3
to E20. The offspring were weaned at postnatal day 28
and were maintained until use. The animals at the time of
the experiments were 8-12 weeks old with body weight
between 250 and 350 g.
Drug injection protocols
To measure antinociceptive effects of morphine on off-
spring prenatally exposed to morphine, methadone, and
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mg/kg, s.c., and subjected to the tail-flick test. Rats were
treated with morphine twice a day (9:00 and 17:00), and
the morphine-induced antinociception was measured
after the first injection of morphine every day. To investi-
gate antinociceptive effects of methadone on prenatally
methadone-exposed offspring, the testing dose of metha-
done was 5 mg/kg. Although methadone has a longer
duration of action than morphine in humans, its half-life
is similar to morphine (70-90 minutes) in rats [21]. In this
test, the methadone injection protocol was similar to the
morphine protocol as described above. To measure anti-
nociceptive effects of buprenorphine on the prenatally
buprenorphine-exposed offspring, rats were injected
with buprenorphine, 1.5 mg/kg, s.c., and underwent the
analgesic test [22]. Buprenorphine has longer duration of
action than morphine and methadone in rats; hence, they
were injected with buprenorphine only once a day.
Analgesia Test
The tail flick test was carried out on rats using a modified
method of Dai et al. [23]. The tail flick latency was
defined by the time (seconds) the animal withdrew the
tail from a heat source (bulb, 8 V/50 W, OSRAM, Ger-
many), and was measured using a semiautomated
machine (Model 7369, Ugo Basile, Italy). The infrared
intensity of the tail-flick machine was set at 45, which
produced a baseline tail flick latency of 2-3 seconds and
the cut-off time was set as 10 sec to prevent tissue dam-
age. The rat was put in a restrainer for 5 min for adaption
before the tail-flick test was performed. To measure the
analgesic effect of opioid agonists, animals were sub-
jected to the tail-flick procedure once a day to minimize
the learning effects. All experimental animals were ran-
domly selected from different litters to ensure a general
effect in the population. The antinociceptive effects were
presented as the area under the time-response curve
(AUC = latency × time).
Data analyses and statistics
All data were analyzed using GraphPad Prism software.
Results were expressed as mean ± SEM. Behavioral data
were analyzed by an unpaired Student's t-test, linear
regression, and one-way or two-way ANOVA followed by
post-hoc Tukey's multiple comparison. A P value < 0.05
was considered significant.
Results
Prenatal effects of opioids on the offspring
Results showed that administration of all three opioids
(full μ-receptor agonist-morphine/methadone and partial
agonist-buprenorphine) decreased the total body weight
gain from E3 to E20 in dams. Though the body weight
significantly decreased in dams after chronic opioid
administration, the average number of pups per litter and
the average body weight of the offspring on the first day
of birth did not differ significantly from the saline con-
trols. One week after birth, the body weight of the off-
spring showed a lower increase in prenatally
buprenorphine-exposed rats. This phenomenon, how-
ever, did not occur in adulthood (8-12 weeks) (data not
shown). There was no difference in the fatality of neona-
tal rats between the saline and morphine/methadone
groups; fatality, however, was significantly higher in the
prenatally buprenorphine-exposed group than in the
saline controls. Fatality among the offspring at P2-P10 of
the prenatally buprenorphine-exposed group was also
significantly higher than the morphine or methadone
prenatally exposed group and saline controls. The results
reveal that opioid administration caused changes in
weight and neonatal mortality, especially for prenatal
exposure to buprenorphine. Effects of prenatal opioid
administration on the gross observations of the offspring
are summarized in Table 1.
Effects of prenatal morphine administration on morphine-
induced supraspinal antinociception
There was a significant decrease of the antinociceptive
activity in prenatally morphine-exposed rats in compari-
son with the prenatal saline controls after the first injec-
tion of morphine (Figure 1A). Daily administration of
morphine resulted in tolerance development in rats. At
the 7th systemic injection of morphine, antinociceptive
activity was significantly different between the prenatally
saline- and morphine-exposed offspring, with the latter
group showing remarkably fewer antinociceptive effects
than the saline controls (Figure 1B). The daily recording
of the antinociceptive response to morphine revealed that
the prenatally morphine-exposed offspring developed a
tolerance to morphine more quickly than the saline group
(F(1, 114) = 4.333, p < 0.05) (Figure 1C). Female offspring
exhibited results similar to those of the male offspring in
morphine-induced antinociceptive effects (data not
shown). These results indicate that prenatally morphine-
exposed animals developed a tolerance to morphine
more quickly after multiple systemic morphine injec-
tions.
Effects of prenatal methadone administration on 
methadone-induced supraspinal antinociception
Postnatal acute treatment with methadone did not result
in different antinociceptive response between the prena-
tally methadone-exposed offspring and the saline con-
trols (Figure 2A). Rats in both groups also developed
tolerance to methadone after repeated injection of the
drug. At the 7th methadone injection, animals exhibited a
decreased analgesic effect of methadone; but there was
no difference between the prenatally methadone-exposed
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the daily changes in methadone-induced tolerance on the
prenatal methadone-exposed offspring showed no differ-
ence from the saline controls (F(1, 31) = 0.535, p = 0.471)
(Figure 2C). In the female offspring, similar results were
obtained (data not shown). These results indicate that
acute methadone administration produced the same anti-
nociceptive activity in both prenatally methadone-
exposed and saline groups. It also shows that the toler-
ance development to methadone was not altered in pre-
natally methadone-exposed offspring.
Effects of prenatal buprenorphine administration on 
buprenorphine-induced supraspinal antinociception
Results showed that postnatal acute injection with
buprenorphine did not result in a different antinocicep-
tive response between the prenatally buprenorphine-
exposed offspring and the saline controls (Figure 3A).
The animals showed a limited antinociceptive response
of buprenorphine at the 4th injection of buprenorphine
(Figure 3B). In addition, the daily recoding of the data
presented a similar development of tolerance between the
two groups (F(1, 31) = 0.073, p = 0.789) (Figure 3C). The
female offspring exhibited similar results (data not
shown). The antinociceptive response of buprenorphine
showed no difference in the offspring of prenatally
exposed buprenorphine and saline controlled group.
Duration of antinociception in prenatally saline-exposed 
animals to morphine, methadone, and buprenorphine
Analyses of the data from the above mentioned experi-
ments on the antinociception in prenatally exposed saline
animals are presented in Figure 4. In animals receiving
the first injection of buprenorphine, the duration of anti-
nociception was longer than the ones received morphine
or methadone (Figure 4A). However, there was no differ-
ence in antinociceptive activity between the morphine-
and methadone-injected groups (Figure 4A). Further-
more, there was a notable decrease in antinociceptive
response after the 2nd administration of buprenorphine,
compared with that of the animals receiving the 3rd
administration of morphine or methadone (Figure 4B);
moreover, the slope of tolerance development was
steeper than that of the morphine or methadone group
(Figure 4C). These results suggest that acute buprenor-
phine administration produced better antinociceptive
ability than that of the morphine or methadone treated
group. In contrast, chronic buprenorphine exposure
developed faster tolerance than the other two opioids in
rats.
Effects of prenatal morphine, methadone and 
buprenorphine administration on morphine-induced 
supraspinal antinociception
The offspring of all three opioids prenatally exposed rats
developed a faster tolerance to morphine. As shown in
Figure 5A, the antinociceptive effect was decreased in all
prenatally opioid-exposed offspring after acute morphine
treatment. Similar analgesic response curves were found
in both morphine and methadone prenatally exposed
rats. However, buprenorphine prenatally exposed rats
were less responsive to morphine-induced antinocicep-
tion (Figure 5A). All prenatally opioid-exposed groups
developed tolerance to morphine after repeated adminis-
tration of morphine (Figure 5B). The prenatally
buprenorphine-exposed group, however, exhibited much
less sensitivity to morphine-induced analgesic effects, as
compared to morphine or methadone prenatally treated
groups (Figure 5B). Comparing the AUC of 1st and 7th
morphine administration in different prenatally opioid-
exposed rats, these results revealed that the rates (slopes)
of tolerance development to morphine in all opioid-
Table 1: Effects of prenatal exposure to opioids on offspring
Saline Morphine Methadone Buprenorphine
Mean ± SEM
Number of offspring per litter 10.9 ± 0.2 10.5 ± 0.3 9.8 ± 0.3 10.2 ± 0.3
Fatality (%) 0.69 ± 0.33 0 0 7.1 ± 2.38**
Fatality occurred in the offspring (%) (P2-P10) 0.21 ± 0.14 0 0.56 ± 0.56 12.14 ± 7.02*
Body weight increase in the dams (g) (E3-E20) 148.1 ± 2.7 132.3 ± 4.2** 121.3 ± 3.3*** 136.4 ± 3.7*
Body weight of the offspring at birth (g) 6.8 ± 0.1 7 ± 0.1 6.6 ± 0.1 6.9 ± 0.1
Body weight of the offspring on day 7 (g) 14.7 ± 0.3 16.3 ± 0.5* 14.5 ± 0.4 13.5 ± 0.4*
*Significantly different compared to saline group, p < 0.05
**Significantly different compared to saline group, p < 0.01
***Significantly different compared to saline group, p < 0.001
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phine, F(1, 71) = 4.411, p < 0.05; methadone F(1, 55) = 14.771,
p < 0.001; buprenorphine, F(1, 55) = 72.624, p < 0.001).
However, the development of tolerance to morphine did
not differ between the morphine and methadone prena-
tally treated groups (F(1, 54) = 0.684, p = 0.412). Similar
results were also obtained in the female offspring (data
not showed). These results indicate a cross-tolerance
occurred in the prenatally opioid-exposed offspring after
postnatal morphine administration. The prenatally
buprenorphine-exposed offspring showed a significantly
higher cross-tolerance to morphine than the prenatally
morphine- or methadone-exposed offspring.
Discussion
The goal of this study was to compare effects of prenatal
exposure to morphine, methadone, and buprenorphine
on offspring when they were re-exposed to opioids at
adulthood. Treatments with all these opioids caused
weight loss in dams but did not directly affect the birth
weight of the offspring. Though the weight of the off-
spring did not differ on the first postnatal day, the pups in
the buprenorphine group showed a significant loss in
body weight after one week, that may reflect the potential
existence of neonatal abstinence syndrome. During the
tail-flick testing period at age 8-12 weeks, there was no
difference in the average of body weight in all of the opi-
oid treated groups. Prenatal exposure to morphine
enhanced the rate of tolerance development to morphine
in the offspring. However, development of tolerance to
Figure 1 Tolerance development to morphine in prenatally mor-
phine-exposed male rats. (A) The latency and AUC of rats after receiv-
ing first injection of morphine. (B) The latency and AUC of rats after 
receiving 7th injection of morphine. (C) Rate of tolerance development 
to morphine in morphine or saline prenatally exposed rats. The ani-
mals more quickly developed a tolerance to morphine than the prena-
tally saline-exposed controls (F(1, 114) = 4.333, p < 0.05). All data are 
expressed as mean ± S.E.M, (N = 19 per group), *p < 0.05, ***p < 0.001 
compared to saline control.
Figure 2 Tolerance development to methadone in prenatally 
methadone-exposed male rats. (A) The latency and AUC of rats after 
receiving first injection of methadone. (B) The latency and AUC of rats 
after receiving 7th injection of methadone. (C) Rate of tolerance devel-
opment to methadone in methadone or saline prenatally exposed rats. 
There was no difference in tolerance development to methadone (F(1, 
31) = 0.535, p = 0.471) between the methadone and saline prenatally 
exposed groups. All data are expressed as mean ± S.E.M, (N = 4 per 
group).
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or buprenorphine-exposed offspring, respectively, was
not observed any difference with prenatally saline
exposed controlled group. Furthermore, all prenatally
opioids-exposed rats showed faster development of toler-
ance to morphine. Most notably, the prenatally buprenor-
phine-exposed group exhibited much less sensitivity to
morphine-induced antinociceptive effect, compared to
the morphine and methadone prenatally treated groups.
The effect of prenatal exposure to opioids that was
observed in the behaviors when the animals were chal-
lenged with opioid at adulthood indicates that prenatal
opioid administration may cause long-term changes in
offspring.
The decrease in body weight in opioid-treated dams
might be due to less consumption of food [24]. The dose
of methadone used was higher than that of morphine in
this study to mimic the therapeutic procedure in human.
However, a notable catatonic effect was observed in
methadone s.c. injected dams in comparison with the
morphine-injected group (data not shown). The marked
catatonic effect of methadone on rats might lead to the
lower weight increase in methadone-administrated dams
than other groups. Buprenorphine is the newest drug
used to treat heroin addicts. Several clinical studies have
Figure 3 Tolerance development to buprenorphine in prenatally 
buprenorphine-exposed male rats. (A) The latency and AUC of rats 
after receiving first injection of buprenorphine (B) The latency and AUC 
of rats after receiving 4th injection of buprenorphine. (C) Rate of toler-
ance development to buprenorphine in buprenorphine or saline pre-
natally exposed rats. There was no difference in tolerance 
development to buprenorphine (F(1, 31) = 0.073, p = 0.789) between the 
buprenorphine and saline prenatally exposed groups. All data are ex-
pressed as mean ± S.E.M, (N = 4 per group).
Figure 4 Antinociceptive response in prenatally saline-exposed 
male rats after acute or the third (or second) injection of different 
opioids. Rats received an acute injection of morphine (10 mg/kg), 
methadone (5 mg/kg), or buprenorphine (1.5 mg/kg), s.c., at age 8-12 
weeks. (A) The latency and the AUC of the first morphine, methadone, 
or buprenorphine injection. (B) The latency and the AUC of the 3rd 
morphine and methadone or the 2nd buprenorphine injection. (C) 
Rate of tolerance development to different opioids in prenatally saline-
exposed rats. The rate of tolerance development showed a steeper 
slope in the buprenorphine-treated group than that of the morphine- 
or methadone-treated group. All data are expressed as mean ± S.E.M, 
(N = 4 in methadone and buprenorphine treatment group; N = 19 in 
morphine treatment group), *p < 0.05, ***p < 0.001 compared to bu-
prenorphine group.
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neonatal abstinence syndrome in infants [8,14]. Previous
studies showed no mortality occurred in prenatal expo-
sure to 3 mg/kg/day of buprenorphine in rats [25]. How-
ever, higher mortality in the offspring with the same dose
of buprenorphine administrated to dams was observed in
our study. Our results agree with those in a previous
study by Robinson and Wallace [20], that higher dose (3
mg/kg) of buprenorphine increased the number of still-
births and raised the mortality index, indicating that
higher dose of buprenorphine might induce complex
effects or serious systemic toxicity to the offspring.
In agreement with previous reports [17-19], our study
found faster decreases in the antinociceptive response to
morphine among prenatally morphine-exposed offspring
than among the controls. However, some studies
obtained opposite results demonstrating that prenatal
exposure to morphine enhanced antinociceptive
response to morphine in adult rats [24,26]. This discrep-
ancy might be due to different injection schedules (short
term with low dose) or measurement methods (hot plate)
used in experimental design. Several reports provided
possible mechanisms to explain the prenatally morphine-
induced tolerance to morphine, including changes in opi-
oid receptor density [17,27,28], intracellular cAMP levels
[29], G protein mRNA levels [30], and expression of
endogenous opioids [31]. Prenatal morphine exposure
increased μ-opioid receptor protein and mRNA expres-
sion at P1 and P7; but the expression returned to the nor-
mal level at P14 [27]. Other studies [17] also showed that
μ-opioid receptor binding of the whole brain homogenate
of P14 offspring of rats did not differ between the prena-
tally saline- and morphine-exposed groups. Nevertheless,
autoradiographic study in P14 rats revealed that the den-
sity of the μ-opioid receptor was significantly decreased
in the striatum, thalamus, and amygdala, but not in the
midbrain, nucleus accumbens (NAc), hippocampus, or
cortex in the prenatally morphine-exposed offspring [17],
suggesting that changes in opioid receptor density in the
offspring of morphine prenatally exposed animals are
region specific. Evidence available also demonstrates sex-
dependent effects in μ-opioid receptor densities in the
brain of animals prenatally exposed to morphine. Prena-
tally morphine-exposed male rats showed an increase in
μ-opioid receptor densities in the NAc and posteromedial
cortical amygdala, and a decrease in the basolateral
amygdala. However, the changes in μ-opioid receptor
densities were dependent on ovarian hormones in the
female rat [32]. Though the results showed a gender dif-
ference in μ-opioid receptor densities, the antinociceptive
response to opioids did not reveal gender difference in
our study.
We obtained no difference in antinociceptive response
to methadone in prenatally saline- and methadone-
exposed rats. However, a previous study showed contro-
versial results that prenatal exposure to methadone
enhanced antinociceptive response to methadone in
adult rats [33]. The difference in these findings of anti-
nociceptive response seems due to different measure-
ment methods for antinociceptive response (hot plate vs.
tail flick) and age (120 days vs. 60 days) used in experi-
mental design. It is well known that pharmacologic pro-
files of methadone are similar to morphine and they also
have similar antinociceptive effects by peripheral subcu-
taneous injection [34]. However, tolerance development
to methadone in the prenatally methadone-exposed rats
was not observed. This is different from what we
obtained in the case of morphine. A possible explanation
may be the use of racemic mixture of methadone, which
is a μ-opioid receptor agonist and also an N-methyl-D-
aspartate (NMDA) antagonist in our study. Davis and
Inturrisi [35] used d-methadone to block morphine-
induced tolerance and NMDA-induced hyperalgesia.
Their results indicate that methadone-induced antinoci-
ceptive response may be a net outcome of methadone
acting on two different classes of receptors that have
opposing regulating functions on opioid-induced anti-
Figure 5 Cross-tolerance development to morphine in morphine, 
methadone or buprenorphine prenatally exposed rats. (A) Tail-
flick latency and the area under the curve (AUC) in animals after receiv-
ing the first injection of morphine, 10 mg/kg, s.c. (B) Tail-flick latency 
and the AUC in animals after receiving the 7th injection of morphine, 
10 mg/kg, s.c. All data are expressed as mean ± S.E.M, (N = 9 in prena-
tally methadone and buprenorphine exposed group; N = 19 in prena-
tally morphine and saline exposed group), *p < 0.05, ***p < 0.001 
compared to saline control; ++P < 0.01, +++P < 0.001 compared to mor-
phine; #P < 0.05, ##P < 0.01 compared to methadone.
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different results of antinociceptive response and toler-
ance development to morphine and methadone.
In addition, our study obtained similar antinociceptive
response and development of tolerance to morphine in
prenatally methadone- and morphine-exposed offspring.
The morphine-induced tolerance in prenatally metha-
done-exposed animals might also be due to opioid recep-
tor expression or binding affinity. Prenatal methadone
treatment induced sustained decreases in both δ- and μ-
opioid receptors in the hypothalamus but not in the cere-
bral cortex [36]. A previous study by Darmani et al. [37]
did not obtain changes in the expression of μ-receptors
when animals were prenatally exposed to methadone,
6.3-9.0 mg/kg/day, from gestation days 7 to 20. However,
when animals were chronically prenatally exposed to
methadone, μ-opioid receptor affinity in both fetal and
maternal brain homogenates at day 20 of the pregnancy
was reduced [37]. Darmani et al. [37] also proposed that
the effect of prenatal exposure to methadone induced an
increase in the Kd of μ-opioid receptor binding as a tran-
sient effect that returned to the control value at day 7
after delivery. However, the region specificity of opioid
receptor expression remains unclear.
In this study, we also demonstrated that prenatally
saline-exposed rats developed tolerance to buprenor-
phine more rapidly than to morphine or methadone
treatment. This confirmed the previous finding that
higher tolerance development to the opioid occurred not
only in a high-efficacy opioid, morphine, but also in a
low-efficacy opioid, buprenorphine [38]. Buprenorphine
induced broad and complicated effects in the neural sys-
tem due to its action on μ-, κ-, δ-, and ORL-1 receptor.
The mechanism of faster tolerance development to
buprenorphine in prenatally saline-exposed rats may due
to higher receptor affinity and slower dissociation of the
drug from the receptors [12,38]. Repeated treatment of
buprenorphine induced even greater hyperanalgesia than
morphine, indicating that chronic buprenorphine treat-
ment may reset the pain threshold [38]. It has been
reported that buprenorphine-induced antinociceptive
response is via the μ-opioid receptor [39]. Moreover, it
also has been shown that morphine or buprenorphine-
induced antinociception was significantly reduced in ani-
mals after they received chronic administration of
buprenorphine [40]. This indicates that a primary factor
for buprenorphine to induce faster tolerance develop-
ment in prenatally saline-exposed rats may be a signifi-
cant alteration of the μ-opioid receptor after
buprenorphine treatment.
We were the first to demostrate that the prenatally
buprenorphine-exposed rats at age 8-12 weeks showed
faster tolerance development to morphine. Previous
study showed that rats prenatally exposed to methadone
or to low or high doses of buprenorphine exhibited more
resistance to morphine-induced antinociception in 4-day
postnatal pups [20]. Robinson et al. [20] also found that
morphine ED25 values were highly increased in pups pre-
natally exposed to buprenorphine, compared with metha-
done after morphine challenge. Methadone increased the
ED25 of morphine when the pups exposed to methadone
in both pre- and postnatal stage. However, pups exposed
to buprenorphine either prenatally, postnatally, or both
pre- and postnatally were more resistant to the antinoci-
ceptive response to morphine. According to this finding,
Robinson et al. noted that buprenorphine seemed to have
a greater ability than methadone to induce tolerance to
morphine and did so in a dose-related manner [20]. How-
ever, our results provided direct evidence to show that
prenatal exposure to buprenorphine caused faster devel-
opment of tolerance by daily challenge with morphine,
than prenatally saline-, morphine-, and methadone-
exposed groups at adulthood. Since buprenorphine is
very lipid soluble and dissociated slowly from the recep-
tors [12,38], prenatal buprenorphine administration may
remain in the body of the offspring till the postnatal
period; hence, it may antagonize the effects of morphine.
However, according to our study, that the experiment was
conducted at adulthood ruled out the residual effects of
buprenorphine in the offspring. Earlier studies suggested
that daily repeated exposure to buprenorphine reduced
the morphine-induced analgesia in naive rats [38,40,41],
suggesting that buprenorphine could produce cross-tol-
erance to morphine in normal condition. However, the
mechanism of the cross-tolerance occurred in the drug-
free of opioid prenatally exposed offspring awaits further
studies. Possible regulatory mechanism might be associ-
ated with changes in opioid or opioid-like receptor densi-
ties. Prenatal exposure to a higher dose of buprenorphine
caused a reduction in the expression of μ-opioid receptor
and an increase of κ-opioid receptor in the brain of P1
offspring [42]. While Belcheva et al. [42,43] speculated a
transient effects of burprenorphine that the receptor den-
sities of brain homogenates returned to normal at P7, the
differential distributions on specific brain areas at adult-
hood warrant further studies. Recently, buprenorphine
has been shown to act as an agonist on the ORL-1 recep-
tor [12], which is expressed as early as E12 in the cortical
plate, basal forebrain, brainstem, and spinal cord, and
which may play important roles in maturation of stress
and pain circuitry [44]. It is also a type of pain-related
receptor that is involved in buprenorphine-induced anti-
nociceptive response [39]. Therefore, buprenorphine may
target several classes of receptors during brain develop-
ment; hence, prenatally administrated buprenorphine
may have a greater impact on brain development than
other opioids.
Chiang et al. Journal of Biomedical Science 2010, 17:46
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In summary, our results confirmed and extended those of
previous studies. We compared three types of opioids in
the same analgesic test condition to verify the effect of
prenatal exposure to opioids on the offspring at their
adulthood. Although methadone and buprenorphine are
considered safer substances than morphine for treating
heroin addicts, prenatal exposure to opioids has been
shown to induce faster tolerance development to mor-
phine. We found that prenatal exposure to buprenor-
phine showed higher mortality and much less sensitivity
to morphine, indicating that buprenorphine in higher
doses may not be an ideal maintenance drug for treating
pregnant women. Therefore, this study has provided fur-
ther evidence to show that prenatal effects of opioids on
the opioidergic system exhibit long-term changes even at
adulthood. Furthermore, several previous studies sug-
gested that the changes of opioid receptors in prenatal
exposure to opioids may be the primary factor in behav-
iors; however, details of the changes of the opioid recep-
tors in different brain regions are still unclear. For this
reason, we will further examine region specificity of pre-
natal opioid exposure on different opioid receptors in rats
at their adulthood in a future investigation. Finally, higher
doses of buprenorphine caused notably more serious side
effects than other opioids in this study, which could pro-
vide a reference in selecting doses for clinical usage in
treating pregnant women who are heroin addicts.
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